AUGUST 09, 2023 THERAPEUTICS Better Therapeutics Team Frank Karbe Diane Gomez-Thinnes Chief Commercial Officer Disclaimer Certain statements in this Presentation may be considered forward-looking statements, within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," " ...

Mark Heinen - Chief Financial Officer Thomas Flaten - Lake Street Capital Markets Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode. After the speakers' presentation, thereÂ'll be a question-and-answer session. [Operator Instructions]. And please be advised today's conference is being recorded. We are confident we provide a compelling value proposition to payers, offering cost predictabilit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 | --- | --- | |-------------------------------------------------------------------------------|------------------------------------------| | | | | Commission File Number: | 001-39864 | | BETTER THERAPEUTICS, INC. | | | Delaware | 85-3472546 | | ( State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 548 Market St. #49404 | | | San Francisco, CA (Address of principal executive offices) | 9 ...

And finally, a decrease in HbA1C and outpatient visits were cited most in terms of measures for a successful diabetes treatment. We look forward to taking these valuable insights as we move into meetings with key supporters at the national level while developing our VISN-level coverage approach. As we refine our plans for market entry, the first phase in our launch will be focused on continuing efforts to expand coverage amongst payers. Covered lives will be a key metric and determinant of success for us. W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the transition period from ____________ to ______________ Page Item 1. Legal Proceedings 26 Item 1A. Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 67 Item 3. Defaults Upon Senior Securities 68 Item 4. Mine Safety Disclosures 68 Item 5. Other Information 68 Item 6. Exhibits 69 Signatures 70 | --- | --- | |-------|-------------------------------------------------------------------------------------- ...

Company Participants Conference Call Participants Operator I would now like to turn the call over to Mark Heinen, Chief Financial Officer. Please begin. Thank you, operator. Good morning, everyone, and welcome to the Better Therapeutics Conference Call. Our press release was issued this morning and can be found in the Investors section of corporate website bettertx.com. During today's call, we will provide a business update a financial overview of the fourth quarter and fiscal year 2022 and provide our outl ...

Coverage and Reimbursement 31 To optimize payer reimbursement coverage following a potential commercial launch, we are generating evidence to substantiate the value of BT-001 with longer-term data related to usage and outcomes in a real world setting. This is additive to the evidence generated from our six-month randomized controlled pivotal trial. We are conducting such real world evidence studies in partnerships with Mass General Brigham, Colorado Prevention Center Clinical Research, University of Colorad ...

Better Therapeutics, Inc. (OTC:BTTX) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial R ...

n | www.bookmark.com/art/an/and/au/mat/multion/arma Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases THIRD QUARTER 2022 EARNINGS CONFERENCE CALL NOVEMBER 14, 2022 THERAPEUTICS Disclaimer This presentation ("Presentation") is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. ("BetterTX" or the "Company") nor any of its respective affiliates nor any of its or their control persons, officers, dir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. Delaware 85-3472546 ( State or other jurisdiction of incorporatio ...